(Q37827403)

23 August 2017

3 references

18 July 2021

19 July 2021

Hydroxychloroquine: from malaria to autoimmunity (English)

1 reference

23 August 2017

0 references

0 references

1 reference

18 July 2021

anti-inflammatory agent

1 reference

19 July 2021

Ilan Ben-Zvi

1

0 references

Yehuda Shoenfeld

series ordinal

4

object named as

Yehuda Shoenfeld

1 reference

23 August 2017

2

Shaye Kivity

1 reference

23 August 2017

3

Pnina Langevitz

1 reference

PubMed ID

21221847

23 August 2017

language of work or name

1 reference

1 April 2012

3 references

Clinical Reviews in Allergy & Immunology

23 August 2017

18 July 2021

19 July 2021

3 references

23 August 2017

18 July 2021

19 July 2021

42

1 reference

23 August 2017

2

1 reference

23 August 2017

145-153

1 reference

https://scigraph.springernature.com/pub.10.1007/s12016-010-8243-x

23 August 2017

0 references

cites work

Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

New concepts in antimalarial use and mode of action in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Chloroquine, quinine, procaine, quinidine, tricyclic antidepressants, and methylxanthines as prostaglandin agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Respiratory function in systemic lupus erythematosus: relation with activity and severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Low-dose oral chloroquine in the treatment of porphyria cutanea tarda

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Treatment of generalized granuloma annulare with hydroxychloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: An open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Effects of chloroquine on viral infections: an old drug against today's diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

The anti-HIV-1 activity of chloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Effect of medication on microvascular vasodilatation in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Chloroquine inhibits stimulated platelets at the arachidonic acid pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Insights into atherosclerosis therapy in antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Effect of a malaria suppression program on the incidence of African Burkitt's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

The lysosomotropic agent, hydroxychloroquine, delivered in a biodegradable nanoparticle system, overcomes drug resistance of B-chronic lymphocytic leukemia cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Cell growth inhibition, G2/M cell cycle arrest, and apoptosis induced by chloroquine in human breast cancer cell line Bcap-37.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Control of mammary tumor cell growth in vitro by novel cell differentiation and apoptosis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Chloroquine inhibits colon cancer cell growth in vitro and tumor growth in vivo via induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Chloroquine inhibits cell growth and induces cell death in A549 lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Kikuchi-Fujimoto disease: an amazing response to hydroxychloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Kikuchi-Fujimoto disease: hydroxychloroquine as a treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Granulomatous infiltration of the talus and abnormal vitamin D and calcium metabolism in a patient with sarcoidosis: successful treatment with hydroxychloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine for subglottic stenosis: a novel therapy in the battle for air.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Sensory neuronopathy with Ro antibodies: response to combination immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Growth inhibitory and differentiation effects of chloroquine and its analogue on human leukemic cells potentiate fetal hemoglobin production by targeting the polyamine pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Antimalarial Drug Toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Glucose-6-phosphate dehydrogenase deficiency: mechanisms of drug-induced hemolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Oral mucosal hyperpigmentation secondary to antimalarial drug therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

21 January 2018

Chloroquine ototoxicity

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Cardiomyopathy related to antimalarial therapy with illustrative case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine-induced myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine-induced toxic myopathy causing respiratory failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Chloroquine neuromyotoxicity. Clinical and pathologic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Evidence of transplacental passage of hydroxychloroquine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine in lupus pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Pregnancy outcome following first trimester exposure to chloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8243-X

Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty

21 January 2018

1 reference

12 December 2020

Immunologic concepts of light reactions in lupus erythematosus and polymorphous light eruptions. I. The mechanism of action of hydroxychloroquine

1 reference

12 December 2020

Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective

1 reference

12 December 2020

Ocular toxicity of hydroxychloroquine

1 reference

12 December 2020

Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study.

1 reference

12 December 2020

In Vivo Chloroquine-induced Inhibition of Insulin Degradation in a Diabetic Patient with Severe Insulin Resistance

1 reference

12 December 2020

SPECTROPHOTOMETRIC STUDIES OF THE INTERACTION OF CHLOROQUINE WITH DEOXYRIBONUCLEIC ACID

1 reference

12 December 2020

The history of antimalarials.

1 reference

12 December 2020

The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs.

1 reference

12 December 2020

Skeletal sarcoidosis: successful treatment with hydroxychloroquine.

1 reference

12 December 2020

Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies.

1 reference

12 December 2020

[Quinines--past and present].

1 reference

12 December 2020

Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties.

1 reference

12 December 2020

Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells.

1 reference

12 December 2020

Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Palindromic rheumatism: a response to chloroquine

1 reference

12 December 2020

Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine

1 reference

12 December 2020

Effect of chloroquine on insulin and glucose homoeostasis in normal subjects and patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver

1 reference

12 December 2020

Treatment of lupus erythematosus with mepacrine

1 reference

12 December 2020

The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus.

1 reference

12 December 2020

Drugs for discoid lupus erythematosus

1 reference

12 December 2020

Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis.

1 reference

12 December 2020

The history of lupus erythematosus. From Hippocrates to Osler

1 reference

12 December 2020

10.1007/S12016-010-8243-X

Identifiers

DOI

1 reference

23 August 2017

0 references

1 reference

PubMed ID

21221847